Oral immunotherapy for hazelnut allergy: a single-center retrospective study on 100 patients

Abstract

BACKGROUND Food allergies negatively affect quality of life and can be a significant medical burden. Allergic reactions to cashew nuts can often be severe and are rarely outgrown. The Ana o 3 protein is an immuno-dominant cashew allergen. Ana o 3 is a small 13kDa protein composed of 2 subunits held together by disulfide bonds that can be disrupted by treatment with reducing agents. The stability and solubility properties of Ana o 3 make it an excellent target for detection methods and tools.

Integrating oral immunotherapy into clinical practice

“…3 Oral immunotherapy (OIT) trials have primarily focused on peanut, cow's milk, and egg; however, wheat, tree nuts, and sesame OIT trials have been conducted, as well as multiallergen OIT. 2,[4][5][6][7][8][9][10][11] Only in 2020 was the first food allergy treatment, a peanut OIT drug called Palforzia (Aimmune Therapeutics, Brisbane, Calif), approved by the Food and Drug Administration (FDA). A peanut epicutaneous immunotherapy patch, Viaskin Peanut (DBV Technologies, Montrouge, France), was under FDA review.…”